32, Songdo Gwawak-ro
Yeonsu-gu
Incheon 21984
South Korea
82 3 2219 7838
https://voronoi.io
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Sunghwan Kim Ph.D. | Chief Technology Officer | N/A | N/A | N/A |
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.
El ISS Governance QualityScore de Voronoi, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.